bioRxivCancer Biology
Effectors enabling adaptation to mitochondrial complex I loss in Hurthle cell carcinoma
R. K. Gopal, V. R. Vantaku, A. Panda, B. Reimer, S. Rath, T.-L. To, A. S. Fisch, M. Cetinbas, M. Livneh, M. J. Calcaterra, B. Gigliotti, K. Pierce, C. B. Clish, D. Dias-Santagata, P. M. Sadow, L. J. Wirth, G. H. Daniels, R. Sadreyev, S. Calvo, S. Parangi, V. Mootha
Abstract
Oncocytic (Hurthle cell) carcinoma of the thyroid (HCC) is genetically characterized by complex I mitochondrial DNA mutations and widespread chromosomal losses. Here, we utilize RNA-seq and metabolomics to identify candidate molecular effectors activated by these genetic drivers. We find glutathione biosynthesis, amino acid metabolism, mitochondrial unfolded protein response, and lipid peroxide scavenging, a safeguard against ferroptosis, to be increased in HCC. A CRISPR-Cas9 knockout screen in a new HCC model reveals which pathways are key for fitness, and highlights loss of GPX4, a defense against ferroptosis, as a strong liability. Rescuing complex I redox activity with the yeast NADH dehydrogenase (NDI1) in HCC cells diminishes ferroptosis sensitivity, while inhibiting complex I in normal thyroid cells augments ferroptosis induction. Our work demonstrates unmitigated lipid peroxide stress to be an HCC vulnerability that is mechanistically coupled to the genetic loss of mitochondrial complex I activity. SignificanceOncocytic (Hurthle cell) carcinoma of the thyroid (HCC) is a unique tumor with a remarkable accumulation of mitochondria. HCC harbors unique genetic alterations, including mitochondrial DNA (mtDNA) mutations in complex I genes and widespread loss-of-heterozygosity in the nuclear DNA. With less favorable clinical outcomes, new therapies for HCC are needed, especially since these tumors show intrinsic resistance to radioactive iodine, which is one of the main treatments for metastatic well-differentiated thyroid cancer. An absence of authentic HCC cell lines and animal models has hindered the mechanistic understanding of this disease and slowed therapeutic progress. In this study, we describe the transcriptomic and metabolomic landscape of HCC and present new HCC models that recapitulate key mtDNA and nuclear DNA alterations. A targeted CRISPR-Cas9 knockout screen in an HCC cell line highlights the molecular programs nominated by our -omics profiling that are required for cell fitness. This screen suggests that lipid peroxide scavenging, a defense system against an iron-dependent form of cell death known as ferroptosis, is a vulnerability in HCC that is coupled to complex I loss, and that targeting this pathway may help patients with HCC.
- organism: human
- assay: bulk RNA-seq
- assay: metabolomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mitochondrial-encoded complex I impairment induces a targetable dependency on aerobic fermentation in Hürthle cell carcinoma of the thyroid
A. R. Frank, V. Li, … D. G. McFadden·bioRxiv·Aug 16, 2022
- Loss of heterozygosity exposes germline mutations in complex I and drives Warburg metabolism in oncocytic carcinoma of the thyroid
Celia de la Calle Arregui, Anderson R. Frank, … David G. McFadden·Science AdvancesPeer-reviewed·Jul 3, 2026
- Stress-induced vtRNA1-1 modulates redox homeostasis and ferroptosis susceptibility in hepatocellular carcinoma cells
EunBin Kong, Daniel Sánchez‐Taltavull, … Norbert Polacek·bioRxiv·Mar 31, 2026
- HIF-2α drives an intrinsic vulnerability to ferroptosis in clear cell renal cell carcinoma
Yilong Zou, Michael J. Palte, … Stuart L. Schreiber·bioRxiv·Aug 9, 2018
- Forward genetic screens identify mechanisms of resistance to small molecule lactate dehydrogenase inhibitors
A. R. Frank, F. Vandiver, D. G. McFadden·bioRxiv·Sep 30, 2023
- PBRM1-VHL cooperation rewires lipid and iron metabolism to promote ferroptosis resistance in clear cell renal cell carcinoma
Guanming Jiao, Luisa F. Baracaldo-Lancheros, … Emily C. Dykhuizen·bioRxiv·May 6, 2026